Oculis Holding (NasdaqGM:OCS) Valuation Check As Privosegtor Wins FDA Breakthrough Therapy Status [Yahoo! Finance]
Oculis Holding AG - Ordinary shares (OCS)
Company Research
Source: Yahoo! Finance
See our latest analysis for Oculis Holding. The breakthrough therapy designation appears to have coincided with stronger trading interest, with a 1 day share price return of 4.72% and 7 day share price return of 15.35% at a latest share price of $23.07. Over longer periods, the stock shows a 15.35% year to date share price return alongside a 9.08% 1 year total shareholder return and a 3 year total shareholder return of around 13x, which suggests momentum has recently picked up again after earlier gains. If this kind of late stage eye care pipeline appeals to you, it could be a good moment to see what else is setting up in healthcare stocks With Oculis trading at $23.07 and flagged as having an intrinsic discount and a very large gap to analyst targets, the key question is whether the recent run has left more value on the table or whether the market is already pricing in future growth. On a P/B of 8.2x at a last close of $23.07, Oculis Holding trades well above both its indust
Show less
Read more
Impact Snapshot
Event Time:
OCS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCS alerts
High impacting Oculis Holding AG - Ordinary shares news events
Weekly update
A roundup of the hottest topics
OCS
News
- Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis [Yahoo! Finance]Yahoo! Finance
- Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare ConferenceGlobeNewswire
- Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis [Yahoo! Finance]Yahoo! Finance
- Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic NeuritisGlobeNewswire
- Oculis (NASDAQ:OCS) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
OCS
Earnings
- 11/10/25 - Beat
OCS
Sec Filings
- 12/9/25 - Form EFFECT
- 12/5/25 - Form POS
- 12/1/25 - Form 424B3
- OCS's page on the SEC website